{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:09:17Z","timestamp":1779196157203,"version":"3.51.4"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title\/><jats:p>On October 24, 2019, a marketing authorization valid through the European Union (EU) was issued for gilteritinib monotherapy for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an Fms-like tyrosine kinase 3 (FLT3) mutation. Gilteritinib inhibits FLT3 receptor signaling and proliferation in cells exogenously expressing FLT3 including FLT3 internal tandem duplication (ITD), FLT3 D835Y, and FLT3 ITD D835Y, and it induced apoptosis in leukemic cells expressing FLT3 ITD. The recommended starting dose of gilteritinib is 120 mg (three 40 mg tablets) once daily. Gilteritinib was evaluated in one, phase III, open-label, multicenter, randomized study of gilteritinib (n =\u2009247, gilteritinib arm) versus salvage chemotherapy (n =\u2009124, salvage chemotherapy arm) in patients with relapsed or refractory AML with FLT3 mutation. Overall survival (OS) was statistically significantly different between the two groups with a median OS of 9.3 months in the gilteritinib arm compared with 5.6 months for salvage chemotherapy (hazard ratio, 0.637; 95% confidence interval, 0.490\u20130.830; p = .0004 one-sided log-rank test). The most common adverse reactions with gilteritinib treatment were blood creatine phosphokinase increase, alanine aminotransferase increase, aspartate aminotransferase increase, blood alkaline phosphatase increase, diarrhea, fatigue, nausea, constipation, cough, peripheral edema, dyspnea, dizziness, hypotension, pain in extremity, asthenia, arthralgia, and myalgia. The objective of this article is to summarize the scientific review of the application leading to regulatory approval in the EU.<\/jats:p><\/jats:sec><jats:sec><jats:title>Implications for Practice<\/jats:title><jats:p>Xospata was approved in the European Union as monotherapy for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an Fms-like tyrosine kinase 3 (FLT3) mutation. Gilteritinib resulted in a clinically meaningful and statistically significant improvement of overall survival compared with salvage chemotherapy. At the time of the marketing authorization of gilteritinib, there were no approved standard therapies specifically for adult patients diagnosed with relapsed or refractory AML with FLT3 mutation. In terms of safety, the overall accepted safety profile was considered manageable.<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0976","type":"journal-article","created":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T10:51:58Z","timestamp":1583837518000},"page":"e1070-e1076","source":"Crossref","is-referenced-by-count":19,"title":["The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an<i>FLT3<\/i>Mutation"],"prefix":"10.1093","volume":"25","author":[{"given":"Kyriaki","family":"Tzogani","sequence":"first","affiliation":[{"name":"European Medicines Agency, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde","family":"R\u00f8shol","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands"},{"name":"Statens legemiddelverk, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helga Haugom","family":"Olsen","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands"},{"name":"Statens legemiddelverk, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida B.","family":"Aas","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands"},{"name":"Statens legemiddelverk, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne L\u00f8iten","family":"Dalhus","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands"},{"name":"Statens legemiddelverk, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gro Dahlseng","family":"H\u00e5konsen","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands"},{"name":"Statens legemiddelverk, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila Sortvik","family":"Nilssen","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands"},{"name":"Statens legemiddelverk, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vibeke","family":"Lindberg","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands"},{"name":"Statens legemiddelverk, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats","family":"\u00d8kvist","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands"},{"name":"Statens legemiddelverk, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f8rg","family":"Bolstad","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands"},{"name":"Statens legemiddelverk, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ir\u0113na","family":"Rogovska","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands"},{"name":"Z\u0101\u013cu valsts a\u01f5ent\u016bra, Riga, Latvia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalja","family":"Karpova","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands"},{"name":"Z\u0101\u013cu valsts a\u01f5ent\u016bra, Riga, Latvia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Enzmann","sequence":"additional","affiliation":[{"name":"Committee for Medicinal Products for Human Use (CHMP), Amsterdam, The Netherlands"},{"name":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Gisselbrecht","sequence":"additional","affiliation":[{"name":"Hospital Saint Louis, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Pignatti","sequence":"additional","affiliation":[{"name":"European Medicines Agency, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,3,10]]},"reference":[{"key":"2021122510443891200_onco13283-bib-0001","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.3390\/medicina54010005","article-title":"Incidence and mortality patterns of acute myeloid leukemia in Belgrade, Serbia (1999-2013)","volume":"54","author":"Maksimovic","year":"2018","journal-title":"Medicina (Kaunas)"},{"key":"2021122510443891200_onco13283-bib-0002","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10552-007-9097-2","article-title":"Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997\u20132002","volume":"19","author":"Yamamoto","year":"2008","journal-title":"Cancer Causes Control"},{"key":"2021122510443891200_onco13283-bib-0003","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2021122510443891200_onco13283-bib-0004","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.ejca.2012.05.024","article-title":"RARECARE Working Group. Incidence, survival and prevalence of myeloid malignancies in Europe","volume":"48","author":"Visser","year":"2012","journal-title":"Eur J Cancer"},{"key":"2021122510443891200_onco13283-bib-0005","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","article-title":"Medical Research Council Adult Leukaemia Working Party. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia","volume":"111","author":"Gale","year":"2008","journal-title":"Blood"},{"key":"2021122510443891200_onco13283-bib-0006","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/sj.leu.2403838","article-title":"Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: A meta-analysis","volume":"19","author":"Yanada","year":"2005","journal-title":"Leukemia"},{"key":"2021122510443891200_onco13283-bib-0007","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.leukres.2004.02.009","article-title":"Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy","volume":"28","author":"Tiesmeier","year":"2004","journal-title":"Leuk Res"},{"key":"2021122510443891200_onco13283-bib-0008","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic Relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122510443891200_onco13283-bib-0009","first-page":"19","article-title":"Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia","volume":"88","author":"Moreno","year":"2003","journal-title":"Haematologica"},{"issue":"suppl 13","key":"2021122510443891200_onco13283-bib-0010","doi-asserted-by":"crossref","first-page":"CT184a","DOI":"10.1158\/1538-7445.AM2019-CT184","article-title":"Gilteritinib significantly prolongs overall survival in patients with relapsed\/refractory (R\/R) acute myeloid leukemia (AML): Results from the phase III ADMIRAL trial","volume":"79","author":"Perl","year":"2019","journal-title":"Cancer Res"},{"key":"2021122510443891200_onco13283-bib-0011","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008","edition":"4th ed."},{"key":"2021122510443891200_onco13283-bib-0012","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122510443891200_onco13283-bib-0013","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: A multicentre, first-in-human, open-label, phase 1-2 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021122510443891200_onco13283-bib-0014","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1111\/cas.13749","article-title":"Clinical profile of gilteritinib in Japanese patients with relapsed\/refractory acute myeloid leukemia: An open-label phase 1 study","volume":"109","author":"Usuki","year":"2018","journal-title":"Cancer Sci"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2019-0976","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0976","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0976","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/7\/e1070\/41920623\/oncolo_25_7_e1070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/7\/e1070\/41920623\/oncolo_25_7_e1070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T05:09:04Z","timestamp":1666069744000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/7\/e1070\/6443390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,10]]},"references-count":14,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,3,10]]},"published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0976","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7,1]]},"published":{"date-parts":[[2020,3,10]]}}}